Holen Sie sich die Stockscreener-App
57.12
0.30%
0.22
Handel nachbörslich:
57.11
-0.010
-0.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$56.90
Offen:
$57.45
24-Stunden-Volumen:
5.66M
Relative Volume:
0.50
Marktkapitalisierung:
$116.64B
Einnahmen:
$48.48B
Nettoeinkommen (Verlust:
$7.27B
KGV:
16.03
EPS:
3.5626
Netto-Cashflow:
$11.91B
1W Leistung:
-0.35%
1M Leistung:
+1.10%
6M Leistung:
+8.89%
1J Leistung:
+12.59%
1-Tages-Spanne:
$56.77
$57.60
1-Wochen-Bereich:
$55.26
$57.60
52-Wochen-Spanne:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
57.12 | 116.19B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,133.00 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
240.88 | 573.71B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.63 | 397.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.05 | 298.26B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.05 | 293.69B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-12-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
A Congress Member Sold Up To $65K In Bristol-Myers Squibb Stock: Here's What You Need To Know - Benzinga
Bristol Myers Squibb Company $BMY Stake Lifted by Xponance LLC - MarketBeat
ICICI Prudential Asset Management Co Ltd Sells 39,000 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb’s AI Overhaul And Oncology Trials Shape Value Story - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Takeda’s Zasocitinib Beats BMS’s Sotyktu In Moderate-To-Severe Plaque Psoriasis - Citeline News & Insights
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial - Reuters
Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue. - The Motley Fool
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Benzinga
Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest - pharmaphorum
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test - Yahoo Finance
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Bristol Myers Squibb Links Brazil Lung Cancer Access To Long Term Story - Yahoo Finance
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Bristol-Myers Squibb Company (BMY) Featured in Citrini's Bullish Healthcare Basket - GuruFocus
BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study - Insider Monkey
Mariska Hargitay launches Bristol Myers Squibb's Myeloma Awareness Campaign - Indian Pharma Post
Inside Bristol Myers’ AI-powered procurement overhaul - CFO Dive
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.00% on Jun 8: A Full Analysis - TradingKey
Disciplined Core Equity Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Competitive approach better than restricting deals with China? - BioWorld News
Bristol Myers Squibb Tests CELMoD Research for Multiple Myeloma - Koran Manado
Mariska Hargitay Partners With Bristol Myers Squibb For Cancer Campaign - Koran Manado
Mariska Hargitay Honors Dad Mickey In Bristol Myers' Myeloma Campaign 06/08/2026 - MediaPost
Bristol Myers Squibb launches myeloma awareness campaign - Investing.com
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease - 巴士的報
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease – Company AnnouncementFT.com - Financial Times
Bristol-Myers Squibb (BMY) Investor Outlook: Analyzing a Promising 10.14% Upside and 4.40% Dividend Yield - DirectorsTalk Interviews
Israel Englander Heavily Boosts Bristol Myers Squibb Position - HarianBasis.co
Assessing Bristol Myers Squibb (BMY) Valuation After Fresh EU Opdivo Approval And New Phase 3 Oncology Data - simplywall.st
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know - Yahoo Finance
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Form 11-KAnnual report of employee stock purchase, savings and similar plans - ADVFN
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Loomis Sayles Strategic Income Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
How Investors May Respond To Bristol Myers Squibb (BMY) Winning EU Nod For First-Line Opdivo Regimen - Yahoo Finance
Bristol-Myers Squibb Co (BMY) Shares Surge 3.4% -- What GF Score of 78 Tells Investors - GuruFocus
Bristol Myers Squibb Adds New Late Stage Oncology Opportunity With Izalontamab - simplywall.st
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study - Yahoo Finance
Pharma’s ‘ugly sister’ is finally ready to offer beautiful returns - Investors' Chronicle
Bristol-Myers Squibb Outperforms Earnings Expectations Amid Market Turbulence - asatunews.co.id
Bristol-Myers Squibb Cancer Wins Test Investor Patience On Valuation - Yahoo Finance
Bristol Myers Squibb vs Pfizer Dividend Stock Comparison 2026News and Statistics - IndexBox
Painful psoriatic arthritis gets new oral option with FDA Sotyktu approval - Stock Titan
BMY Collaborates with Arcus Biosciences on Clinical Trial for Ca - GuruFocus
Radiation-emitting implant improves outcomes after brain cancer surgery - Reuters
Bristol-Myers Squibb stock (US1078421011): modest move as oncology data and institutional flows draw - AD HOC NEWS
Westpac Banking Corp Purchases 46,386 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate - PMLiVE
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? - The Motley Fool
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):